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OBJECTIVES: We aimed to evaluate the clinical, societal
and economic outcomes of olanzapine treatment com-
pared to treatment with standard antipsychotics in out-
patients with multiple schizophrenic episodes and subse-
quent yearly rehospitalizations. METHODS: The present
study comprised two stages. Within the first (clinical)
stage a mirror image 24-week cost-effectiveness study
was performed. Data were evaluated from 30 schizo-
phrenic patients (ICD-10). Drug efficacy assessment in-
cluded PANSS. Social functioning was evaluated with the
original checklist. Economic analysis based on resource
utilization data. Within the second stàge a Markov simu-
lation model over a hypothetical 5-year period has been
developed to compare the overall costs and cost-effective-
ness of olanzapine with those of standard treatment. RE-
SULTS: During the maintenance phase of the study,
olanzapine-treated patients achieved a statistically signifi-
cant greater improvement than ones treated with stan-
dard antipsychotics on overall measures of effectiveness.
In spite of high acquisition cost of olanzapine, total med-
ical costs were not significantly more (nearly 10 %). In-
cremental cost-effectiveness ratio for olanzapine of 5 rou-
bles (1998 values) per disability-free day gained over the
trial period. The direct cost per patient was calculated to
be 56000 roubles higher for 5-year` therapy with olanza-
pine. However the net savings per olanzapine-treated pa-
tient was 40.000 roubles from societal perspective by sig-
nificantly increasing productivity and producing more
time in a disability-free state. The results of analysis were
not robust in a sensitivity analysis, including variations in
the frequency, duration and/or cost of hospitalization
and/or acquisition cost of olanzapine. CONCLUSIONS:
Olanzapine offered an economically justifiable therapeu-
tic option in the long-term management of the special
subpopulation of patients with frequent rehospitaliza-
tions.
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In December 1994, naltrexone, marketed under the
brand name Revia, became the first adjunctive medica-
tion in almost 50 years approved by the FDA for treat-
ment of alcoholism. Despite the evidence of its efficacy in
randomized clinical trials, the use of naltrexone is not
widespread. OBJECTIVE: To identify possible barriers
to the use of naltrexone and other new medications in the
treatment of alcoholism. METHODS: Focus groups were
conducted in Washington, DC. The first comprised phy-
sicians who treat substance abuse, recruited nationally
through a professional association and physician consult-
ant referrals. The second comprised individuals who had
been treated for alcoholism in the past three years and
were in recovery, recruited locally through a newspaper
advertisement. The physician group was taped and tran-
scribed; the patient group was not taped in order to pro-
tect confidentiality. RESULTS: Public and provider lack
of information were identified as key reasons why nal-
trexone has not been used more widely. Patients also
pointed out medication side effects, the philosophy of Al-
coholics Anonymous (AA), the high price of naltrexone,
and stigma as barriers. In addition, physicians noted lack
of evidence of efficacy in practice, difficulty measuring ef-
ficacy in practice, lack of physician time for patient man-
agement, patient reluctance to take medication, uncer-
tainty in identifying appropriate patients for naltrexone,
and lack of knowledge of and attitudes toward the use of
medications among counselors as barriers. The findings
will be used to inform the design of a national survey of
providers. CONCLUSIONS: The findings suggest that
physicians will not adopt innovations based solely on the
clinical literature. While millions of dollars have been in-
vested in the development of new alcoholism medica-
tions, licensing medications may not result in significant
changes in treatment without educational and marketing
efforts to promote the medications through the diverse
members of the alcoholism treatment community.
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OBJECTIVE: The purpose of this retrospective study is
to examine both schizophrenia-related direct costs and
total (schizophrenia plus non-schizophrenia) direct costs
among Texas Medicaid patients who have been diag-
nosed with a schizophrenic disorder and have been initi-
ated on one of two atypical antipsychotics (olanzapine or
risperidone). METHODS: Services and prescription utili-
zation and cost data were retrieved for 3,072 patients
with schizophrenia who were initiated on olanzapine or
risperidone between 1997 and 1998. Each patient was
followed for one year from initiation of therapy. Multi-
variate analysis was used to control for a wide range of
factors (drug choice, patient demographics, pre-utiliza-
